Our results identify a unique FTO-mediated and m6A-mediated mechanism in promoting melanoma tumorigenesis and resistance to anti-PD-1 blockade, and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce resistance and improve the anti-melanoma response. The gene discussed is PDCD1; the disease is melanoma.